TY - JOUR
TI - Belimumab as Add-on Therapy in Lupus Nephritis
AU - Ward, M.
AU - Tektonidou, M.G.
JO - The New England journal of medicine
PY - 2020
VL - 383
TODO - 12
SP - 1184-1185
PB - Massachussetts Medical Society
SN - null
TODO - 10.1056/NEJMe2027516
TODO - azathioprine;  B lymphocyte antibody;  belimumab;  calcineurin inhibitor;  cyclophosphamide;  glucocorticoid;  mycophenolate mofetil;  placebo;  rituximab;  belimumab;  immunosuppressive agent;  monoclonal antibody, add on therapy;  drug efficacy;  Editorial;  estimated glomerular filtration rate;  human;  infection;  lupus erythematosus nephritis;  phase 3 clinical trial (topic);  priority journal;  prognosis;  randomized controlled trial (topic);  risk benefit analysis;  treatment response;  lupus erythematosus nephritis, Antibodies, Monoclonal, Humanized;  Humans;  Immunosuppressive Agents;  Lupus Nephritis
TODO - null
ER -